

**Supplementary Table S1: Exclusion criteria**

Exclusion criteria	<ul style="list-style-type: none"><li>• Isolated thumb osteoarthritis</li><li>• HOA secondary to other known causes (e.g., gout, reactive arthritis, RA, psoriatic arthritis, spondyloarthropathies, septic arthritis)</li><li>• Skin psoriasis</li><li>• Current skin disease of the left ear interfering with the application of the auricular electrode for stimulation (eczema, urticarial lesion, skin infection, external otitis, etc.)</li><li>• Auditory canal not adapted to the application of the ear electrode</li><li>• Known history of cardiac rhythm disturbances, atrioventricular block &gt; 1st degree, conduction disturbances</li><li>• Symptomatic orthostatic hypotension or history of recurrent vagal syncope</li><li>• History of vagotomy</li><li>• Documented sleep apnea</li><li>• Existence of a painful syndrome of the upper limbs, which would interfere with assessment of HOA symptoms.</li><li>• Fibromyalgia</li><li>• Use of other medical devices electrically active (pacemaker, TENS for chronic pain)</li><li>• Use of oral, intramuscular or intra-articular or intravenous corticosteroids, immunosuppressants (methotrexate, sulfasalazine, leflunomide, biological disease-modifying antirheumatic drugs), of hyaluronic acid infiltration in the finger joints in the previous 3 months</li><li>• Any new OA treatment of the hand within the previous month, including physiotherapy and a new digital orthosis.</li><li>• Hand surgery planned during the study.</li><li>• Use of any investigational (unapproved) medication within 3 months prior to the screening.</li><li>• Serious and uncontrolled concomitant disease, including cardiovascular, nervous system, pulmonary, renal, hepatic, endocrine, gastrointestinal or epileptic disease, which, in the opinion of the investigator, would make the study unfeasible.</li><li>• Pregnant or breastfeeding woman</li><li>• Patient under legal protection (guardianship or curatorship) and patient deprived of liberty</li><li>• Participation in other research intervention or in the exclusion period following a previous research if applicable</li><li>• Patient without social care</li></ul>
--------------------	--

	<ul style="list-style-type: none"> <li>• Taking NSAIDs &lt; 48 hours</li> </ul>
--	---

**Supplementary Table S2: Reported adverse events of 4 weeks of the tVNS in EHOA patients.**

<b>Patient number</b>	<b>Adverse event</b>	<b>Related to device (Yes/No/uncertain)</b>	<b>Severity</b>	<b>Recovery at 4 weeks</b>
<b>2</b>	Bilateral conjunctivitis	No	Minor	Yes
<b>6</b>	Local tingling	Yes	Minor	Yes
<b>6</b>	Hand pain when trying to replace the earpiece	Yes	Mild	Yes
<b>6</b>	Post-stimulation fatigue	Yes	Mild	Yes
<b>7</b>	Local tingling	Yes	Minor	Yes
<b>7</b>	Insomnia	Uncertain	Mild	No
<b>8</b>	Local tingling	Yes	Minor	Yes
<b>8</b>	Auricular device desadaptation of the cymba concha		Minor	No
<b>12</b>	Local auricular pain	Yes	Minor	Yes
<b>13</b>	Local auricular pain	Yes	Minor	No
<b>13</b>	Scotoma right eye	No	Minor	No
<b>15</b>	Local auricular pain	Yes	Minor	No
<b>19</b>	Floating body left eye	No	Minor	Yes